{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:04:02Z","timestamp":1788386642153,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Common treatment methods for malignant tumors include surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, etc., among which chemotherapy plays an important role. However, chemotherapy brings corresponding side effects while killing tumor cells, and nausea and vomiting are the most common adverse reactions induced by chemotherapy. It not only affects the patient\u2019s appetite, resulting in malnutrition and electrolyte disturbances, but also reduces the patient\u2019s compliance with treatment, which further aggravates the disease. Thus, it is important to quickly prevent and cure nausea and vomiting induced by chemotherapy (CINV). In addition, with the continuous development of medicine, more and more antiemetic drugs have been developed. At present, the most common antiemetic agents for chemotherapy-induced nausea and vomiting are NK-1R antagonists, 5-HT3R antagonists, and dexamethasone. Surprisingly, olanzapine, often used as a psychotropic drug, has been found to be an effective antiemetic and is similar to other regimens on the safety of medicine. However, although there are numerous studies on the antiemetic effects of olanzapine, its comprehensive application remains unclear. Therefore, this review will elaborate the antiemetic effect of olanzapine in terms of the antiemetic mechanism and the safety, economic cost, dose, administration time, and drug delivery aspects.<\/jats:p>","DOI":"10.3390\/curroncol29110650","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T23:26:32Z","timestamp":1667258792000},"page":"8235-8243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug"],"prefix":"10.3390","volume":"29","author":[{"given":"Xiao-Ling","family":"Zhang","sequence":"first","affiliation":[{"name":"Wenzhou Medical University, Wenzhou 325000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Er","family":"Ying","sequence":"additional","affiliation":[{"name":"The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lee, S.R., Kim, S.M., Oh, M.Y., and Lee, J.M. (2020). Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children. Children, 7.","DOI":"10.3390\/children7090140"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bcp.13242","article-title":"Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: A meta-analysis","volume":"83","author":"Yang","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/CCO.0000000000000450","article-title":"The latest consensus on antiemetics","volume":"30","author":"Herrstedt","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00520-016-3391-z","article-title":"2016 Updated MASCC\/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential","volume":"25","author":"Olver","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00520-018-4115-3","article-title":"Guidelines versus individualized care for the management of CINV","volume":"26","author":"Clemons","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","article-title":"Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis","volume":"24","author":"Yokoe","year":"2019","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","article-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting","volume":"722","author":"Navari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/109662103764978506","article-title":"Olanzapine for intractable nausea in palliative care patients","volume":"6","author":"Jackson","year":"2003","journal-title":"J. Palliat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Saudemont, G., Prod\u2019Homme, C., Da Silva, A., Villet, S., Reich, M., Penel, N., and Gamblin, V. (2020). The use of olanzapine as an antiemetic in palliative medicine: A systematic review of the literature. BMC Palliat. Care, 19.","DOI":"10.1186\/s12904-020-00559-4"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jjco\/hyy114","article-title":"Study protocol for J-SUPPORT 1604 (J-FORCE): A randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy","volume":"48","author":"Hashimoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: A systematic review","volume":"24","author":"Chow","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jjco\/hyx084","article-title":"A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy","volume":"47","author":"Nakashima","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_14","first-page":"CD012555","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults","volume":"9","author":"Sutherland","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2015.12.029","article-title":"A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan","volume":"140","author":"Mizuno","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","article-title":"CINV: Still troubling patients after all these years","volume":"26","author":"Aapro","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"943618","DOI":"10.1155\/2015\/943618","article-title":"Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy","volume":"2015","author":"Ranganath","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","article-title":"Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: A systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature","volume":"29","author":"Chow","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1038\/srep04813","article-title":"A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/SPC.0000000000000206","article-title":"Cancer and chemotherapy-induced nausea and vomiting: A focus on olanzapine","volume":"10","author":"Bosnjak","year":"2016","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10147-016-1069-7","article-title":"Breakthrough chemotherapy-induced nausea and vomiting: Report of a nationwide survey by the CINV Study Group of Japan","volume":"22","author":"Tamura","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"595894","DOI":"10.1155\/2015\/595894","article-title":"Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting","volume":"2015","author":"Navari","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J. Support. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/jco.2015.33.15_suppl.9502","article-title":"Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment","volume":"33","author":"Navari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: A randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"J. Pain Symptom Manag."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"705866","DOI":"10.3389\/fonc.2021.705866","article-title":"The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1007\/s00520-020-05977-x","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients","volume":"29","author":"Chow","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s11096-018-0649-1","article-title":"Olanzapine as antiemetic drug in oncology: A retrospective study in non-responders to standard antiemetic therapy","volume":"40","author":"Slimano","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2147\/CMAR.S280995","article-title":"Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide","volume":"13","author":"Suehiro","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1470-2045(19)30791-0","article-title":"Time to re-think the olanzapine dose","volume":"21","author":"Molassiotis","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"711940","DOI":"10.3389\/fphar.2021.711940","article-title":"Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone","volume":"12","author":"Zubiaur","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11864-020-00804-1","article-title":"The Benefits of Olanzapine in Palliating Symptoms","volume":"22","author":"Davis","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.21037\/apm.2019.08.04","article-title":"A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide","volume":"8","author":"Tienchaiananda","year":"2019","journal-title":"Ann. Palliat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.schres.2013.11.009","article-title":"Olanzapine and clozapine differently affect sleep in patients with schizophrenia: Results from a double-blind, polysomnographic study and review of the literature","volume":"152","author":"Kluge","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16232","DOI":"10.1038\/s41598-018-34618-x","article-title":"Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study","volume":"8","author":"Kawazoe","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00520-018-4593-3","article-title":"Antiemetic use of olanzapine in patients with advanced cancer: Results from an open-label multicenter study","volume":"27","author":"Harder","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.annemergmed.2016.08.008","article-title":"A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department","volume":"69","author":"Cole","year":"2017","journal-title":"Ann. Emerg. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/1060028019831634","article-title":"Intravenous Olanzapine for the Management of Agitation: Review of the Literature","volume":"53","author":"Khorassani","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/NDT.S158339","article-title":"Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia","volume":"14","author":"Katagiri","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Katagiri, H., Fujikoshi, S., Suzuki, T., Fujita, K., Sugiyama, N., Takahashi, M., and Gomez, J.C. (2014). Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry, 14.","DOI":"10.1186\/s12888-014-0313-9"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/0018578718823484","article-title":"Intravenous Olanzapine in a Critically Ill Patient: An Evolving Route of Administration","volume":"55","author":"Lorenzo","year":"2020","journal-title":"Hosp. Pharm."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/650\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:06:25Z","timestamp":1760144785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["curroncol29110650"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29110650","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}